News: Articles and Publications

For more information, contact: media@gatesmri.org Cambridge, Mass., USA (28 May 2024) — The Bill & Melinda Gates Medical Research Institute (Gates MRI) today announced the appointment of Patrice Matchaba, MD, as Chief Executive Officer (CEO), starting June 10, 2024. He succeeds the current CEO, Emilio Emini, PhD, who recently announced his retirement, effective on June 30, 2024. Dr. Matchaba began his career as a physician in South Africa before working for more than two decades in the pharmaceutical industry. In his time with Novartis Global Pharmaceuticals in the US and Switzerland, Dr. Matchaba gained expertise in drug development, global product registration, and market access. Prior to joining the institute, his most recent roles were President of Novartis’ U.S. Foundation and Novartis Group Head of Global Health. Before joining…

A large Phase 3 trial will evaluate whether the M72/AS01E vaccine candidate can protect adolescents and adults from pulmonary tuberculosis. Clinical trial site at University of the Witwatersrand, Johannesburg, South Africa, is first of up to 60 sites in seven countries. The M72/AS01E vaccine candidate could be the first new TB vaccine in 100 years if proven effective.

Calibr, a division of Scripps Research dedicated to the “bench to bedside” development of transformative medicines, and the Bill & Melinda Gates Medical Research Institute (Gates MRI), today announced a strategic licensing agreement to advance development of a novel investigational compound for tuberculosis treatment.